Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are at least 6 to 7 months behind. Why do you think the price has moved? Do you really think that Mayo would test a circuit board? Do you really believe Mayo would expose their reputation without pre-testing?
I will let you believe what you want. I find it hard to believe.
They have had the working model since the announcement on Mayo---actually before because Mayo had to pretest before taking on. Not sure why the disconnect here.
What a move congrats Value investor what price level next ??? Thoughts on volume ???
You said==
"Also, like we have been saying know technology is for hundreds of applications."
Actually 100,000 !
"What is the Potential of Know Labs that can collect biometric data on their technology platform at the rate of 100,000 molecules per second on a NONINVASIVE basis?
How valuable will the Know Labs technology platform be? But ONE of those molecules is glucose (and DexCom trades at a market cap of $ 24 BILLION based upon just this ONE molecule). What are the other 99,999? What are the potential revenues for the other 99,999?"
Between KNWN and Particle the $ 16 will look cheap in the future IMHO.
Hang in there and do not sell out too early.....to reap the rewards you have waited years and years.
Do you have a write up about Tom Fournier ??-----I see nothing out there. Not on Know website. So what year did Know acquire the Fournier technology?
Thanks
2011 Wow !!! Congrats. This must feel like forever. I feel you will be rewarded for your unbelievable patience.
Thank you. So your nephew and brother are shareholders of KNWN. That is a good sign and probably why you are a shareholder also.
Particle is the icing on the cake.
They were worthless originally. Why repeating?
The non-medical applications of Know's technology platform is as great as the medical applications.
If a company were to acquire Know they would pay zero for the non-medical applications. Particle is a way to set aside and commercialize the non-medical applications.
Particle could in the future be spun off to shareholders and be a separate public company with SEPARATE management and its own funding.
The creation of Particle is the largest event for Know in 2020.
Same as the original shareholders. No different !
Lofdog NDA prevents him from discussing Know Labs I imagine it is lasts for 50 years.
Lofdog Come on your "NDA" covers this? Do you know what a NDA is even?
"No longer with Know ??? Why?? Did you see him on your visit?
To me he was critical to everything.
Dr. Mark Tapasak Prior to his academic assignment Tapsak began his work with medical devices with Medtronic, and then with Dexcom. At Dexcom, a multi-billion dollar provider of continuous glucose monitoring (CGM) systems, Dr. Tapsak was the 12th employee. He was involved with inventions that are broad in scope and range from:
Composition of matter, manufacturing techniques for key Dexcom membrane technology
Dexcom sensor design and geometry
Electrochemical performance of Dexcom sensor
Dexcom system design and function
Dexcom biointerface design and composition of matter
As a result of Dr. Tapsak’s work, he currently holds 65 issued United States patents, 52 of which are Dexcom assigned patents. "
lofdog No longer with Know ??? Why?? Did you see him on your visit?
To me he was critical to everything.
Dr. Mark Tapasak Prior to his academic assignment Tapsak began his work with medical devices with Medtronic, and then with Dexcom. At Dexcom, a multi-billion dollar provider of continuous glucose monitoring (CGM) systems, Dr. Tapsak was the 12th employee. He was involved with inventions that are broad in scope and range from:
Composition of matter, manufacturing techniques for key Dexcom membrane technology
Dexcom sensor design and geometry
Electrochemical performance of Dexcom sensor
Dexcom system design and function
Dexcom biointerface design and composition of matter
As a result of Dr. Tapsak’s work, he currently holds 65 issued United States patents, 52 of which are Dexcom assigned patents.
https://www.forbes.com/sites/danieldambrosio/2020/03/26/this-new-england-startup-has-an-analyzer-that-will-detect-coronavirus/#d3efdd87c853
Mar 26, 2020,09:43pm EDT
This New England Startup Is Developing An Analyzer That Will Detect Coronavirus
The person who headed up developing the Anthrax detection machine for the government in 2001 now has his own public diagnostic company utilizing the technology developed then.LexaGene is the public company (TSX.V: LXG OTCQB: Symbol LXXGF) with market cap of $ 59 million.
LexaGene is a biotechnology company developing genetic analyzers for pathogen detection and other molecular markers.
See LexaGene CoronaVirus Press Release
https://lexagene.com/release/2020/lx-analyzer-successfully-detects-coronavirus-rna/
Top Markets Targeted 1) Veterinary Diagnostics-(Market Size $5.4 Billion USD)-ONE Hour turnaround 2) Food Safety –e-Coli-Cannabis-Hemp-etc 48 million illnesses in US (Market Size $ 24 Billion) 3) Clinical Diagnostics ($12.9 Billion USD)-includes pandemics Other Water Safety/ Genotyping/Cruise Ships/Border Crossing etc.
Video testimonial from the veterinary team can be viewed in the following video. The following is a Video of the Beta Prototype TEST at Massachusetts Veterinary Referral Hospital (4 min):
https://lexagene.com/beta-testimonial-video/
References:
Lexagene Website
https://lexagene.com/
https://lexagene.com/subscribe/
Public Company Quote
https://finance.yahoo.com/quote/LXXGF?p=LXXGF
Lexagene Company Presentation
https://lexagene.com/wp-content/uploads/2020/02/LXG_Investor-Presentation_12Feb20web.pdf
This Machine Can Save a Million Lives in 60 Minutes (came out last week.
https://secure.outsiderclub.com/o/web/245869
Forbes “This New Device’s Rapid Pathogen Identification May Be Our Next Big Medical Breakthrough”
https://www.forbes.com/sites/jimvinoski/2019/12/10/this-new-devices-rapid-pathogen-identification-may-be-our-next-big-medical-breakthrough/#4fb24b082f63
Callon Petroleum—CPE
Stock is 7% of Audited Book Value of $8.13 Projected Cash Flow Per Share 2020 $ 2.62 Market Price $ .58 per share
Based upon the greatest Oil Basin in the World the Permian Basin in Texas.
Steven A Webster---Co-Founder of Carrizo
Steve Webster was appointed to the Callon Board in December 2019 in conjunction with the merger of Callon and Carrizo.
Mr Webster was a co-founder of Carrizo for which he served as a director since 1993 and as its Chairman of the Board since June 1997. Since 2016, Mr Webster has served as Managing Partner of AEC Partners, a private equity firm engaged in energy investment which was the successor to Avista Capital Partners, a private equity firm he co-founded in July 2005 and for which he served as Co-Managing Partner.
Mr Webster earned an MBA degree from Harvard Business School, where he was a Baker Scholar, and a BSIM degree and Honorary Doctorate from Purdue University.
Webster Callon Shares owned prior to purchases:
Direct 5,094,924
Wife 245,000
San Felipe Resources Company 43,750
Recent Insider purchases of Callon Shares by Webster:
February 28, 2020 200,000 Shares AT $ 2.12
March 2, 2020 50,000 Shares AT $ 2.13
March 2, 2020 250,000 Shares AT $ 2.10
March 3, 2020 100,000 Shares AT $ 2.05
March 4 , 2020 200,000 Shares AT $ 1.959
March 5, 2020 100,000 Shares AT $ 1.787
March 6, 2020 50,000 Shares AT $ 1.2995
March 6, 2020 300,000 Shares AT $ 1.4814
March 9, 2020 250,000 Shares AT $ .4236
March 10, 2020 200,000 Shares AT $ .512
March 11, 2020 300,000 Shares At $ .4793
March 12, 2020 100,000 Shares At .5161
Total 2,100,000 Shares of Callon
% Increase in Position 39%
Total $ Purchases $ 2,741,345
Average Cost per Share $ 1.31
Insider Gregory Conaway Vice President & Chief Accounting Officer Insider Purchase
Owned prior to Purchases 122,908 Callon Shares
Purchases
March 11, 2020 200,000 shares AT $ .4845 Share
March 19, 2020 100,000 shares AT $ .48 Share
Total owned 422,908 Callon shares after purchases--- Increase in Position 244%
https://finance.yahoo.com/quote/CPE/key-statistics?p=CPE
Audited Book Value $8.13 Per Share
Market Price $ $.58
% Market Price to Book 7% (this is RARE)
Projected Cash Flow 2020 = $ 2.62 Per Share (this is even more rare—selling at 18% cash flow)
Callon has ~70% of Q1 oil hedged at $55.45 and ~60% of full year oil hedged at that price.
No Long Term Debt due until late 2022---no near term maturities
Agree Nick Hodges really did a lot of due diligence on Lexagene. Just an amazing job.
"He wrote a better description of LXXGF than LexaGene has so far. You are wrong. Nick is helping get the word out. You are not."
Lexagene Elevator Summary
One great piece of due diligence. Congrats to Nick Hodge for putting it
together.
https://secure.outsiderclub.com/o/web/245869
This Machine Can Save a Million Lives in 60 MinutesIt detects: coronavirus, SARS, influenza...It detects: E. coli, listeria, staph...
Means nothing. Norchi is the key and people here are seeking answers from no one with any knowledge or expertise.
Purastat is primitive compared to AC5. I know the origins but they failed to advance the original product and failed clinical trials.
Intellectual property is controlled by ARTH.
Ever hear 3-D Matrix speak at a conference? Ever hear what the founder of AC-5 and Purastat say about Purastat?
With 8-12 employees how profitable will ARTH be? Manufacturing is on contract basis. Profit margins estimated to be over 90%.
You should talk with surgeon to get better insight and understanding.
Watching the wrong presentation. Talk with Dr. Kapp as I did.
“For wounds to heal and for patients to require fewer subsequent doctor visits, damaged and devitalized tissue must be properly cut away to obtain healthy, pink tissue, which often bleeds. Unfortunately, wounds are often under treated instead of debrided because they are cared for in outpatient settings not conducive to aggressively treating deeper, bleeding wounds. Arch Therapeutics’ AC5 advanced wound dressing technology could be a breakthrough, democratizing the approach to wound care in a wide range of treatment settings with potential utility across all phases of healing, starting with hemostasis.”
Daniel Kapp, MD Surgeon (Specialties: Plastic Surgery and Wound Care) Chief of Plastic Surgery, Palm Beach Gardens Medical Center Medical Director, Wound Healing Center at Jupiter Medical Center
“With increased numbers of patients on anti-coagulants, bleeding from even small procedures is becoming a more important issue each day. The concept of AC5, which selfassembles on tissue, provides a novel technology that can treat multiple areas of the body and can also be used with other biosurgical technologies. It has tremendous potential in bleeding wounds and may also provide unique solutions to leakage of other fluids such as lymphatics.”
Dennis Orgill, MD, PhD Professor of Surgery, Harvard Medical School (Specialties: Plastic and Reconstructive Surgery) Director of the Brigham and Women’s Hospital Wound Care Center, Boston, MA Principal Investigator, Would Healing & Tissue Engineering Laboratory
https://tinyurl.com/w4g7rr5
This New Device’s Rapid Pathogen Identification May Be Our Next Big Medical Breakthrough
Jim Vinoski
Contributor
Manufacturing
I write about all facets of manufacturing.
LexaGene's LX2 Genetic Analyzer
The U.S. is just finishing up an autumn full of scares around the country over the mosquito-borne EEE virus. During the Thanksgiving holiday, we had yet another large-scale lettuce recall. Now flu season is coming into full swing. So our concerns about pathogens – disease-causing organisms – are spiking right now.
What if we had a piece of technology that could quickly detect and identify those nasty little creatures that cause so much heartache, illness and death, allowing fast diagnoses for illness prevention and treatment? LexaGene, a start-up in Beverly, Massachusetts, may have just that.
The company was founded in 2016 and is publicly traded on the TSX Venture Exchange (TSX.V:LXG) and over the counter in the US (OTCQB:LXXGF). In a post-IPO capital round in October, LexaGene raised $5 million. Their parent company, LexaGene Holdings, Inc., has a market capitalization of over $35 million. The company is on the cusp of the commercial launch of its technology.
“First and foremost, it’s important to identify the problem,” said Dr. Jack Regan, LexaGene’s founder and CEO. “Current diagnostics are failing us. We shouldn’t be getting treatment based on the guess of a physician.” That’s no knock on our doctors, who are doing the best with what they have. The problem is that today’s state of the art diagnostic methods are too slow. Current testing involves culturing samples to allow any microorganisms to grow to a quantity large enough to analyze. This can take days to deliver results, and can often still be inexact.
LexaGene says its LX2 Genetic Analyzer is the answer. It delivers exact results in about an hour. “What makes us so fast versus culturing? We directly amplify the genetic material,” explained Regan. “The instrument amplifies bacterial genetic targets roughly one trillion-fold for easy optical detection. Our technology allows for gold standard testing in both performance and speed.” The technology arose out of work Regan did previously at Lawrence Livermore National Laboratory. “It’s the next generation instrument of what I worked on there,” he said. “The government used it for bio-threat detection – anthrax, plague, and smallpox, for example. In contrast, our instrument can be used across many applications, including clinical diagnostics, food safety, and pandemic prevention. The technology automates a very powerful detection chemistry, making complex testing easy. You essentially load a sample with a cartridge, enter a sample ID, and press ‘Go.’”
Of those multiple applications of the technology, the most obvious is disease detection. “We enable rapid diagnostics, giving physicians the ability to determine the best way to treat their patients,” Regan said. That allows for immediate treatment of the known illness.
It can help with current antibiotic challenges. “The CDC [U.S. Centers for Disease Control and Prevention] sees antibiotic resistance as one of the biggest health challenges of our time,” Regan said. “Better diagnoses will eliminate antibiotic overuse. Right now physicians prophylactically prescribe antibiotics, not knowing whether the symptoms are due to an infection or other medical concern, or whether any prescribed drugs are going to be effective. As a result, patients can spend days on an ineffective antibiotic. If the doctor can quickly detect whether an infection is present and whether drug-resistance factors are present, he or she can prescribe the correct treatment right away.” This offers a better avenue to antibiotic stewardship.
Preventing a pandemic of any kind is another opportunity. “Our technology is perfectly suited to this,” said Regan. “We can configure it for rapid detection of different strains.” The flu is an obvious application. “I did my doctoral work on influenza,” he added. “It’s very deadly. Every year about 30,000 people die, but that’s a drop in the bucket compared with a pandemic, where 33 million might die in the first six months.” Each year’s flu shot can be less than effective if it treats for strains other than the most prevalent one. LexaGene can screen for known strains, then add testing for new strains as they appear, potentially allowing for corrections to the vaccine.
“With next generation sequencing, we can identify the pathogen that causes death early on,” Regan said. “We can then get a test out in two or three days that will provide a rapid way to triage and quarantine those affected.”
Food safety is a big potential application as well. There, producers working to prevent foodborne illnesses rely on laboratory testing that can take days to deliver results. LexaGene’s quick pathogen identification can help reduce the potential for contaminated products reaching consumers, and related illnesses and deaths. They can also help food processors avoid costly product recalls. (Here’s one of my related articlesthat goes into greater detail on this.)
When it comes to a breakthrough new diagnostic device, of course, one concern is sure to pop up: how can we be confident this isn’t the next Theranos? “How do we set readers at ease regarding our technology? Look at the founders and the members of our Board,” said Regan. “Theranos had big names with no experience in diagnostics. At LexaGene, I’ve focused on building our scientific integrity, with Board members who have backgrounds in diagnostics, science and industry work. Personally, I have an intensive background in this particular science from my doctoral studies, work at Lawrence Livermore, and experience in successful startups and larger life science companies. Furthermore, I’ve published numerous times and have numerous issued patents. And we have outside companies already using our technology independently. In contrast, Theranos had none of that. One of the other things that frustrated me about Theranos was that their claims were so unrealistic. They said they could run 200 accurate tests from a single drop of blood, but published studies have shown that the chances of detecting a single pathogen in one drop of blood are less than 50% because bacteria don’t grow to high concentrations in the blood. There’s simply no way they could do what they claimed.”
Regan is focused on the positives of his technology. “We’ve completed numerous beta tests at potential customer locations, and which shows investors that the technology works exceptionally well and is now nearly ready for commercial sales,” he said. “Right now, we’re working on hiring a sales team and in discussions with contract manufacturers. The wheels are in motion for us to hit the ground running. We’re addressing a desperate need,” he added. “We’re perfectly poised to make the transition into sales in mid-2020 and we look forward to sharing stories of our technology saving lives. It’s not that far away.”
Does My Stock or Bond Have Any Value?
Usually, the stock of a Chapter 7 company is worthless and you have lost the money you invested.
https://www.sec.gov/reportspubs/investor-publications/investorpubsbankrupthtm.html
Yes and I call the Company directly and do NOT get answers from social media. To expect answers from social media makes no sense to me. Note that Company has no authority over regulatory authorities.
When does a company have authority over a regulatory body?
I happen to believe they hired Daniel Wadsworth because he accomplished what he is suppose to.
It is all here:
Per Dr. Norchi: “The commercial opportunity is significant and enduring.”
Dr. Norchi Presentation is here:
http://wsw.com/webcast/ldmicro16/register.aspx?conf=ldmicro16&page=arth&url=http://wsw.com/webcast/ldmicro16/arth/index.aspx
Corporate Presentation
https://content.equisolve.net/archtherapeutics/media/c6dc3c52a4e0458fae43779086460ea0.pdf
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems.
Total Outstanding Warrants 25,983,135
Total Exercise Cash $ 16,791,236
Average price per share $ .64
Total Cash raised since inception of Company $ 32,451,250
Market cap fully diluted $ 62,491,041
For every one dollar raised by ARTH it is now valued at $ 1.93
Employees since 2016 8 Employees
Study my previous post on Closure Medical Corporation Versus ARTH
***************************************Outstanding***Price Per Share
Warrant Series D Expires 6/30/20 8,974,389 $ .25
Warrant Series E Expires 5/26/21 4,214,582 $ .438
Warrant Series F Expires 2/20/22 5,991,664 $ .75
Warrant Series G Expires 6/29/23 6,802,500 $ .70
Warrant Series H Expires 5/14/24 8,615,384 $ .40
Series D % Exercised 37.6%
Series E % Exercised 40.3%
Series F % Exercised 0%
Series G % Exercised 0%
Series H % Exercised 0%
Thank you for your valuable input. What are your thoughts on ARTH?
Actually all those ARTH share "sells" are actually allowing people like Blackngold83 to accumulate huge positions. Just normal.
Congrats. Study my post here. Wonder how Arch has accomplished anything with only 8 employees.
https://www.stockgumshoe.com/2017/11/microblog-discussion-page-for-arch-therapeutics-arth/comment-page-3/#comment-4999695
Here is my write ups on 3D Matrix over the years:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=122879986
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=122878638
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=124184793
Show me one human trial by 3D Matrix. They were rejected in Japan during human trials some years ago and another human trial.
They got their CE Mark without a single human trial. CE Mark is based solely on safety.
I believe they lost this lawsuit:
https://ir.archtherapeutics.com/press-releases/detail/518/arch-therapeutics-announces-positive-outcome-of-ruling-from
Without human trials this will go nowhere: 3-D Matrix has launched a hemostat for use in GI endoscopy in Europe
Where are the 3-D Matrix conference presentations?
Arch has the best patent attorneys in the world.
Wow the million $ question. I am very thankful it is here. However would not every surgeon and doctor be interested in being a shareholder if they understood ARTH? So when they do a marketing agreement they will be approaching thousands of doctors who will be aware of AC5 and ARTH. Call 617-431-2313 and ask for CFO Rick Davis and ask what the company is doing to get the word out?? We need new Blood. Call investors relations 1-855-340-2784 and ask if company making presentations to doctors?
ARTH is an easy sell to doctors.
Attributes of AC5
Synthetic peptide
Clear liquid, squirted or sprayed-- Can see and operate through it
Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body-reason it is classified as medical device)
Classified as Medical Devicebecause of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes
Stops bleeding promptly
Faster time to stop bleeding versus five different popular marketed products
Blood thinner agnostic—only hemostasis product that is.
Efficacy even in presence of “blood thinners”
Bioasborbable
Natural amino acids, non-animal
Enables normal healing
Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer
Stores at room temperature
Indefinite shelf life
Simple, effective, versatile, safe universal
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems.
Not at all. I never have cared who owns and who does not. The comparison with Closure only confirms what Arch has accomplished. Closure's pre-tax profitability was huge even with a bloated employee load.
“ARCH Business Model
Our present business model is to operate with a relatively small internal team of key personnel and engage third party service providers to conduct larger scale research, development and manufacturing activities. Our internal team collectively has a broad range of expertise and experience working with and managing third party vendors. This general approach enables us to use the services of third party entities, which are expert in various aspects of our operations, while preserving capital and efficiencies by avoiding certain internal scale-up costs and resource duplication.” END
Closure 2004--- 123 full-time employees, 107 were dedicated to research, development, manufacturing, quality control and regulatory affairs, and 16 were dedicated to administrative activities. Fifteen members of our research, development and regulatory affairs staff have doctoral or advanced degrees (Arch last 6 years 8 employees only—3 with doctoral degrees)
In 1996 Closure completed an 818-patient controlled, randomized clinical trial of DERMABOND at ten sites throughout the United States. (Arch’s human clinical trials have all been small with less than 50 patients at ONE location)
Closure Research & Development Costs 12/31 1996 $ 3.167 million 1997 $ 3.594 million 1998 $ 6.297 million 1999 $6.296 million 2000 $ 5.852 million 2001 $ 5.622 million 2002 $ 6.436 million 2003 $ 8.134 million 2004 $ 10.01 million (Arch highest R&D in last six years is only $2.9 million)
Arch’s AC5 received FDA approval December 17, 2118 allowing for the product to be marketed for external applications.
Arch is adopting multiple selling partner marketing strategy in 2019.
Arch External Applications 1) Diabetic foot ulcers..1 to 1.5 million patients year Annual US Healthcare system cost $11 billion 2) Pressure Ulcers (bedsores) 2.5 million patients year Annual spent on wound care products exceeds $ 15 billion 3) Adhesions 2.5 million patients/year US Form after 70-90% of major absominal surgery & 50-100% of women after pelvic surgery Market growing 15% year Need: Cover, protect, promote moist environment, enable healing Opportunity $ 1 to $2 Billion 4) GI Sealant 2-15% leak rate in anastomoses Significant morbidity and mortality. Significant reoperation rate with added expenses. Opportunity $.5 million to $ 1 Billion and potentially greater 5) Burns 500K patients/year in US Plus many many more
War chest of over 50 patents. Intellectual property is where value is stored. IMHO most of the big R&D is behind us.
This is the person who made it all happen for Arch since 2007--few understand this:
Steven Kates, PhD has worked with Arch Therapeutics since 2007. He is a highly experienced pharmaceutical executive with over twenty years in R&D for both life science products and human therapeutics, Dr. Kates is regarded as a world leading chemist and industry expert in peptide design and manufacture in the biopharmaceutical industry. He has advanced several compounds through drug development from early pre-clinical to early clinical development. He was responsible for the successful development of clinical candidates for both 505(b)2 and NCE applications.
He has held senior positions at Ischemix, Citius Pharmaceuticals, Surface Logix, Consensus and Millipore Corporation.Dr. Kates has authored or co-authored over 100 articles, reviews, and patents, and is a member of the American Chemical Society, the American Peptide Society, and the Association of BioMolecular Research Facilities. Dr. Kates has served as editor of Solid-Phase Synthesis: A Practical Guide and ADMET for Medicinal Chemists: A Practical Guide; guest editor of Biopolymers; co-editor of ADMET for Medicinal Chemists, A Practical Guide; a member of the Editorial Board of International Journal of Peptide Research and Therapeutics (formerly Letters in Peptide Science); and is an ad hoc reviewer for the NIH bio-organic and natural products study section.An Adjunct Professor in the Bouvé College of Health and Sciences, Center for Drug Discovery and College of Professional Studies at Northeastern University, and Visiting Professor of Chemistry at Brandeis University,
Dr. Kates earned his B.S. in chemistry from Bates College and his PhD in Synthetic Organic Chemistry from Brandeis University, and conducted post-doctoral studies at The Massachusetts Institute of Technology. His research interests include solid-phase peptide and organic synthesis as well as synthesis of peptides and small molecules with therapeutic activities for stroke, coronary artery bypass graft (CABG), myocardial infarction (MI) and inhibitors and substrates for kinases, proteases and G-protein coupled receptors.
2006 No difference 2019 Enormous difference Today the products have little similarity. Arch spent an enormous sum to perfect the MIT technology and now has over 50 patents to itself. FDA approval in December 2018 was Arch's confirmation.
Polyphemus No they thought they had a 'better" mousetrap.
We all are going to have to rethink the business model of ARTH:
Closure employees numbered 75 at time of commercialization in 1999. Arch employees total 8 at time of commercialization in 2019. Arch has never had more than 8 employees.
What ARTH has pulled off when compared to Closure is simply amazing.
Until you do a deep dive you come to realize what they have pulled off.
So rather than doing a straight up IPO in 2013 and raising the $ 33.7 million that they raised thus far they elected to do a reverse merger with a warrant strategy that backfired when the stock price went down in stead of up.
This is in the Form 10-K
They were private from 2006 until 2013 where Norchi et al financed.
I have written about this in the past. This mess up created the opportunity that we have today and in the past. They should have done a clean IPO.
ARTH is following the marketing gameplan laid out by Closure Medical (1996-2004) when it was acquired by JNJ in early 2005.
The profit margins were very large and the marketing JV's lucrative for Closure with upfront fees. Closure's medical applications were narrow compared to ARTH.
Please tell ARTH:
Yahoo
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures.
ARTH Press release
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5™ Topical Gel, AC5™, Topical Hemostat1 and AC5™ Surgical Hemostat.1
Only been public since May 20, 2013. Six years. Since May 20, 2013 have raised a total of $ 33,778,823 which is tiny in biotech world.
Per Norchi “premium pricing” on AC5 to reflect its best in class status- Normal is $ 200 to $1,500 per unit. Extremely low manufacturing cost.
They figured out the manufacturing side of the equation very early on. That was one of the very first assignments.
Arch has not been close to commercialization in the past four years.
Corporate Presentation
https://content.equisolve.net/archtherapeutics/media/c6dc3c52a4e0458fae43779086460ea0.pdf